The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1564
ISSUE 1564
January 28, 2019
OTC Primatene Mist Returns
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
January 28, 2019 (Issue: 1564)
The FDA has approved over-the-counter (OTC) sale
of inhaled epinephrine (Primatene Mist – Amphastar),
a nonselective alpha and beta agonist, for temporary
relief of mild symptoms of intermittent asthma in
patients ≥12 years old who have been diagnosed with
mild intermittent asthma by a healthcare professional.
The original version of Primatene Mist, which was
approved by the FDA in 1967, was removed from the
market in 2011 because the metered-dose inhaler (MDI)
contained ozone-depleting chlorofluorocarbon (CFC)
propellants; the new MDI contains hydrofluoroalkane
(HFA) propellants.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: OTC Primatene Mist Returns
Article code: 1564a
Electronic, downloadable article - $45
Article code: 1564a
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
